Neurologic Diseases and Neurogenetics

Summary

This group undertakes the challenges of developing advanced treatments for patients with movement disorders, refractory epilepsy, neuropathies, myasthenia, myopathies, etc., in addition to the work carried out with the Multiple Sclerosis Unit and the Multidisciplinary Unit for Patients with Amyotrophic Lateral Sclerosis (thanks to the collaboration with the Miquel Valls Foundation).he group works in the development of new diagnostic and prognostic biomarkers and clínical, epidemiological studies in neurologial diseases.

619 Publications

Strategic lines

Biomarkers in neurological disease: ALS, MS, Alzheimer's Disease...
New therapeutic strategies in Neurological Diseases
Epidemiology of Neurological Disease: ALS, neurovascular disorders, dementia, Multiple Sclerosis
Lexical access disorders in speech production
Prothrombotic mechanisms in patients with Stroke
Neurophysiological markers in postanoxic patients
Neuronal networks and Epilepsy
Prognostic studies in movement disorders, multiple sclerosis, ALS, neurovascular, dementia...

Selected Publications

Eculizumab as a promising treatment in thymoma-associated myasthenia gravis

Velez-Santamaria, Valentina; Nedkova, Velina; Diez, Laura; Homedes, Christian; Alberti, M. Antonia; Casasnovas, Carlos

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2020, doi: 10.1177/1756286420932035

EXPRESS: Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry

Siegler JE; Cardona P; Arenillas JF; Talavera B; Guillen AN; Chavarría-Miranda A; de Lera M; Khandelwal P; Bach I; Patel P; Singla A; Requena M; Ribo M; Jillella DV; Rangaraju S; Nogueira RG; Haussen DC; Vazquez AR; Urra X; Chamorro Á; Román LS; Thon JM; Then R; Sanborn E; de la Ossa NP; Millàn M; Ruiz IN; Mansour OY; Megahed M; Tiu C; Terecoasa EO; Radu RA; Nguyen TN; Curiale G; Kaliaev A; Czap AL; Sebaugh J; Zha AM; Liebeskind DS; Ortega-Gutierrez S; Farooqui M; Hassan AE; Preston L; Patterson MS; Bushnaq S; Zaidat O; Jovin TG

International Journal Of Stroke. 2020, doi: 10.1177/1747493020959216

Evaluation of Dysphagia in Motor Neuron Disease. Review of Available Diagnostic Tools and New Perspectives

Romero-Gangonells, Elisabet; Nuria Virgili-Casas, M.; Dominguez-Rubio, Raul; Povedano, Monica; Perez-Saborit, Nuria; Calvo-Malvar, Nahum; Barcelo, Maria A.

DYSPHAGIA. 2020, doi: 10.1007/s00455-020-10170-7

Autobiographical memory in epileptic patients after temporal lobe resection or bitemporal hippocampal sclerosis

Miro, Julia; Ripolles, Pablo; Sierpowska, Joanna; Santurino, Mila; Juncadella, Montserrat; Falip, Merce; Rodriguez-Fornells, Antoni

BRAIN IMAGING AND BEHAVIOR. 2020, doi: 10.1007/s11682-019-00113-8

Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment

Andrés-Benito P, Gelpi E, Jové M, Mota-Martorell N, Obis È, Portero-Otin M, Povedano M, Pujol A, Pamplona R, Ferrer I

Neuropathology And Applied Neurobiology. 2020, doi: 10.1111/nan.12681

Selected Projects

Estudio de fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de aducanumab (BIIB037) en pacientes con enfermedad de Alzheimer temprana

Reñe Ramirez, RAMON (Principal investigator (PI))

Funder:

BIOGEN IDEC RESEARCH LIMITED

2016-2020

A GLOBAL, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, RESPONSE-ADAPTIVE DOSE-RANGING STUDY OF BMS-986177, AN ORAL FACTOR XIA INHIBITOR, FOR THE PREVENTION OF NEW ISCHEMIC STROKE OR NEW COVERT BRAIN INFARCTION IN PATIENTS RECEIVING ASPIRIN AND CLOPINDOGREL FOLLOWING ACUTE ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK (TIA)

Cardona Portela, Pere (Principal investigator (PI))

Funder ref.:

CV010-031

2019-2021

A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE CONTROLLED STUDY OF EVOBRUTINIB COMPARED WITH TERIFLUNOMIDE, IN PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS TO EVALUATE EFFICACY AND SAFETY

Martinez Yelamos, Sergio (Principal investigator (PI))

Funder ref.:

MS200527_0080

2020-2021

EVALUACIÓN DE LA TOMA DE IMÁGENES PONDERADAS POR DIFUSIÓN (DWI) Y DE LA TOMOGRAFÍA COMPUTARIZADA DE PERFUSIÓN (TCP) CON DISCORDANCIA CLÍNICA EN LA PRIORIZACIÓN DE ACCIDENTES CEREBROVASCULARES DE TIEMPO DE INICIO DESCONOCIDO Y DE APARICIÓN TARDÍA DURANTE NEUROINTERVENCIONES (DAWN)

Cardona Portela, Pere (Principal investigator (PI))

Funder:

Stryker European Operations BV

2016-2020

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY

Falip Centelles, Mercè (Principal investigator (PI))

Funder ref.:

EP0092

2020-2021

More information

PROJECTS

Title: Activation of the resolution programs of inflammation as a novel therapeuthic approach for the treatment of amyotrophic lateral sclerosis
PI: Povedano Padanes, Mònica
Coordinator: Universitat Autònoma de Barcelona- UAB (Project Leader: Dr. Rubèn López Vales)
Call reference: Health Research 2017 Call for proposals, expediente: HR17-00777
Funder: Fundació “la Caixa”